Circassia averts its cash crunch
Payment of an overdue $120m Astrazeneca milestone, plus two other obligations, has been met through a loan facility with undisclosed terms.
Circassia finds a second way to put investors’ money under threat
Business development decisions have started the clock on a financial time bomb set to go off within the next three months.
Go or no go? Johnson & Johnson awaits Spravato nod
Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.
Biotech flotations remain in high demand
Almost $2bn was raised by drug developers in the third quarter, a period that witnessed two of the largest flotations of pre-revenue companies in recent years.
Where is the IPO class of 2014-15 now?
A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.
